Elevation Oncology (ELEV) said Thursday it is dropping its development of EO-3021, an antibody-drug conjugate for the potential treatment of advanced, unresectable, or metastatic gastric and gastroesophageal junction cancers.
The decision to discontinue clinical development of EO-3021 was based on data from the dose escalation and expansion stages of a phase 1 trial which "deeply disappointed" the company, said Joseph Ferra, president and chief executive officer.
The company said it will continue to advance EO-1022, a potential treatment for patients with HER3-expressing solid breast cancer tumors while beginning a process to evaluate strategic options to maximize shareholder value.
Shares of the company fell more than 24% in recent premarket activity.
Price: 0.3489, Change: -0.122, Percent Change: -24.69
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。